SLC2A1 and cancer: In contrast to the corresponding increased gene expression of glucose transporter 1 (GLUT1) in cancer cells, T cells exhibit a downregulation in GLUT1 expression, which constitutes an inhibitory mechanism by cancer cells to elude the T-cell therapies through bottle-necking T cells’ access to necessary glucose [23,24].